🇺🇸 FDA
Patent

US 9072716

Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells

granted A61KA61K31/00A61K38/164

Quick answer

US patent 9072716 (Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells) held by The United States of America, as represented by the Secretary Department of Health by Human Servies expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary Department of Health by Human Servies
Grant date
Tue Jul 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/00, A61K38/164, A61K38/2086, A61P